Xizang Weixinkang Pharmaceutical Co., Ltd. Class ASSE: 603676

"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

Aug 28, 2026 · Issued by Xizang Weixinkang Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Convening the 2026 Semi-annual Performance Briefing

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Xizang Weixinkang Pharmaceutical Co., Ltd. Class A

"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on the Subsidiary's Acquisition of the Drug Registration Certificate for Multivitamin Injection (12)Aug 8
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on Participation in Subscription of Private Equity Fund SharesAug 4
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on the Termination of the Exclusive License AgreementJul 18
"XIZANG WEIXINKANG PHARMACEUTICAL CO., LTD."Announcement on the Subsidiary's Obtaining the Drug Registration Certificate for Compound Potassium Hydrogen Phosphate InjectionJul 11

All Xizang Weixinkang Pharmaceutical Co., Ltd. Class A news releases